Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) EBITDA (2017 - 2025)

Historic EBITDA for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$142.0 million.

  • Arcus Biosciences' EBITDA fell 3523.81% to -$142.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.0 million, marking a year-over-year decrease of 1792.45%. This contributed to the annual value of -$330.0 million for FY2024, which is 294.12% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' EBITDA is -$142.0 million, which was down 3523.81% from -$8.0 million recorded in Q2 2025.
  • Arcus Biosciences' EBITDA's 5-year high stood at $278.2 million during Q4 2021, with a 5-year trough of -$142.0 million in Q3 2025.
  • Moreover, its 5-year median value for EBITDA was -$78.0 million (2021), whereas its average is -$61.7 million.
  • Over the last 5 years, Arcus Biosciences' EBITDA had its largest YoY gain of 63613.22% in 2021, and its largest YoY loss of 453553.16% in 2021.
  • Arcus Biosciences' EBITDA (Quarter) stood at $278.2 million in 2021, then crashed by 126.6% to -$74.0 million in 2022, then decreased by 22.97% to -$91.0 million in 2023, then fell by 13.19% to -$103.0 million in 2024, then crashed by 37.86% to -$142.0 million in 2025.
  • Its EBITDA was -$142.0 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$122.0 million in Q1 2025.